News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
224 Results
Type
Article (2)
Company Profile (1)
Press Release (221)
Section
Business (39)
Drug Development (33)
FDA (28)
Job Trends (5)
News (108)
Policy (12)
Tag
Academia (1)
Alliances (13)
Approvals (28)
Best Places to Work (5)
Cardiovascular disease (3)
Clinical research (34)
Data (4)
Diabetes (2)
Earnings (7)
Events (17)
FDA (28)
GLP-1 (1)
Healthcare (21)
Job creations (3)
Legal (3)
Metabolic disorders (3)
NextGen: Class of 2025 (1)
Obesity (3)
People (13)
Pharmaceutical (1)
Phase II (5)
Phase III (25)
Pipeline (1)
Postmarket research (5)
Real estate (4)
Regulatory (9)
Date
Last 7 days (1)
Last 30 days (1)
Last 365 days (11)
2025 (4)
2024 (10)
2023 (5)
2022 (1)
2021 (8)
2020 (11)
2019 (15)
2018 (8)
2017 (15)
2016 (27)
2015 (6)
2014 (16)
2013 (17)
2012 (13)
2011 (12)
2010 (23)
Location
Europe (7)
New Jersey (10)
New York (1)
United States (11)
224 Results for "NovoNordiskUS".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
Business
Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes
September 6, 2024
·
5 min read
Press Releases
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
June 9, 2025
·
6 min read
Press Releases
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
March 31, 2025
·
6 min read
Press Releases
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
March 25, 2025
·
9 min read
Press Releases
Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
March 5, 2025
·
10 min read
Press Releases
ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 - The Liver Meeting®
November 19, 2024
·
6 min read
Press Releases
New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight
November 4, 2024
·
6 min read
Press Releases
Novo Nordisk to present new cardiometabolic and renal data, including with semaglutide, at Kidney Week 2024, ObesityWeek®, The Liver Meeting®, and AHA Scientific Sessions 2024
October 24, 2024
·
9 min read
Press Releases
New pooled analysis published in The Lancet demonstrated reduced risk of combined CV death or worsening heart failure with semaglutide
September 2, 2024
·
10 min read
1 of 23
Next
